Drosdiol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drosdiol

Property Description
Active Ingredients Drospirenone, Ethinyl Estradiol
Form Oral Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Pregnancy Prevention, Menstrual Cycle Regulation
Origin Synthetic Hormone Therapy

Drosdiol: Defining the Combined Hormonal Contraceptive

Drosdiol is a systemic, synthetic hormone therapy administered orally in the form of a prescription-only tablet. It is officially classified as a Combined Hormonal Contraceptive (CHC), belonging to the broad pharmacological group of Sex Hormones and Modulators of the Genital System, specifically Progestogens and Estrogens (fixed combinations). This classification indicates that the medicine utilizes two distinct types of active hormonal agents working in concert to achieve its primary purpose, distinguishing it from products containing only a single hormone component. The product is clinically recognized for its high efficacy when used consistently, which is a key factor in its acceptance as a primary method of pregnancy prevention.


Composition and Unique Profile of Active Ingredients

The drug's composition is defined by its two active ingredients: the synthetic estrogen, Ethinyl Estradiol (a derivative of 17beta-estradiol, also known as 17alpha-ethinylestradiol), and the synthetic progestin, Drospirenone. Drospirenone is characterized by its pharmacological profile as a fourth-generation progestin, owing to its capacity to bind to and antagonize the androgen receptor and the mineralocorticoid receptor. This unique dual action provides the product with distinct antiandrogenic activity and antimineralocorticoid activity, features supported by pharmacological properties. This combination is found in several popular brands, including Yasmin and YAZ, and targets women of reproductive age seeking reliable oral contraception.


General Therapeutic Purpose and Primary Benefit

The primary purpose of Drosdiol is highly effective pregnancy prevention (contraception) by reliably influencing the female reproductive endocrine system. Beyond contraception, the hormonal effects inherently support menstrual cycle regulation, contributing to predictable and often lighter withdrawal bleeding. Furthermore, the specialized antiandrogenic activity of the Drospirenone component is associated with the general benefit of helping to manage moderate acne vulgaris in patients who have chosen this oral contraceptive for birth control. The specific hormone combination may also help manage symptoms related to fluid retention.

What side effects are possible with Drosdiol?

Possible Side Effects and Safety Information

Drosdiol's safety profile is primarily defined by the risks associated with combined hormonal contraceptives.

Serious and Clinically Significant Risks

Official documents highlight the risk of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction. The risk of these vascular events is highest during the first year of use and upon restarting the medication after a break.

The medication also carries a risk of malignant neoplasms, specifically an increased risk of breast and cervical cancer, and a rare association with hepatic adenomas or hepatocellular carcinoma, particularly with long-term use.

Due to the anti-mineralocorticoid activity of drospirenone, there is a potential for hyperkalemia (high potassium levels) in high-risk patients. This necessitates contraindication in individuals with renal impairment, hepatic impairment, or adrenal insufficiency. Liver disease and undiagnosed abnormal uterine bleeding are also contraindications.

Common Adverse Reactions

The most commonly reported adverse reactions include menstrual irregularities (such as breakthrough bleeding or spotting), nausea, headache or migraine, breast tenderness, and mood changes.

Safety Monitoring

Patients on Drosdiol should be monitored for signs of thromboembolism and require regular blood pressure checks. Those at high risk for hyperkalemia should have serum potassium levels monitored, especially during the first treatment cycle and when taking certain concomitant medications that may raise potassium.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Drosdiol overdose indicates that acute toxicity is low, and serious ill effects are not typically expected. This assessment is based on reports concluding that overdosage is not likely to be life-threatening or fatal. However, specific immediate actions and specialized monitoring are formally required in case of accidental or intentional overdose.

Documented Overdose Presentations and Toxicity

Element Official Regulatory Statement
Documented Manifestations Nausea, vomiting, and vaginal bleeding (specifically withdrawal bleeding)
Toxicity Classification Overdose is not likely to be life-threatening; no reports of serious ill effects have been documented, including following ingestion by children.
Emergency Action Seek emergency medical attention immediately for suspected overdose and contact a Poison Control Center for guidance.

Supportive Management and Monitoring Requirements

Treatment is mandated to be strictly symptomatic and supportive, as there is no specific antidote known to reverse the effects of the hormonal components. Due to the anti-mineralocorticoid properties of the drospirenone component, specific physiological monitoring is required to manage potential complications.

Mandatory Monitoring Requirements:

  • Serum concentration of potassium and sodium
  • Evidence of metabolic acidosis

These monitoring requirements are crucial for managing potential electrolyte imbalances associated with the drug's unique formulation.

Therapeutic Uses of Drosdiol

Drosdiol: Main Uses and Benefits

Drosdiol is a prescription combined oral contraceptive relevant across therapeutic domains involving Reproductive Health and Symptom Management. The medication is relevant for managing the risk of unwanted pregnancy for women of reproductive potential. It is also commonly used to help with the symptoms of premenstrual dysphoric disorder (PMDD), and is considered relevant for managing symptoms of moderate acne vulgaris in women who choose an oral contraceptive for birth control. This formulation may be part of symptomatic management in contexts where patients require both birth control and supportive symptom management for these specific conditions. This provides supportive relief when symptoms interfere with routine activities.

The indications relevant to this combination include pregnancy prevention, moderate acne vulgaris, and symptoms of PMDD.

“This medication supports patients who seek both birth control and symptomatic relief from certain hormonal discomforts.”


Quick Fact: Relief for Hormonal and Cyclical Discomfort

Drosdiol supports the regulation of the menstrual cycle, which may assist with a more predictable and generally lighter pattern of withdrawal bleeding. Furthermore, it assists with managing subjective discomforts associated with cyclical fluid retention, such as feelings of bloating or swelling, which supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Drosdiol? (Official Regulatory Information)

The eligibility for using Drosdiol (Drospirenone/Ethinyl Estradiol) is strictly defined by regulatory contraindications focusing on specific health conditions and life stages, primarily due to the risk of thrombosis and the drug's hormonal profile.

Contraindicated Populations

The medicine must not be used by individuals with a high risk of arterial or venous thrombotic diseases, including a history of deep vein thrombosis (DVT) or stroke, or those with known hypercoagulopathies (e.g., Protein C deficiency). Use is prohibited in women over 35 years old who smoke.

Additionally, Drosdiol is contraindicated in patients with renal impairment, adrenal insufficiency, liver tumors or disease, uncontrolled hypertension, or diabetes with vascular involvement. Women with a current or history of breast cancer or other hormone-sensitive malignancies are also ineligible.

Age and Life Stage Restrictions

Population Group Eligibility Status (Regulatory)
Pediatric Use Not indicated before menarche; use for acne is for those at least 14 years and post-menarche.
Geriatric Use Not indicated for use in women after menopause (elderly women).
Pregnancy Contraindicated (known or suspected).
Lactation Not recommended; may reduce milk production.

Eligibility is limited to females of reproductive potential who do not present with any of these officially documented contraindications.

What should I know about interactions with other medicines?

Drosdiol Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Drosdiol (Drospirenone/Ethinyl Estradiol) as stated in government regulatory sources.


Contraindicated Combinations

Co-administration of Drosdiol is contraindicated with combination drug regimens used to treat Hepatitis C. This prohibition applies to combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for significant elevations in Alanine Transaminase (ALT) liver enzymes.


Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Classes Official Regulatory Outcome
Metabolic (CYP3A4) Strong or moderate CYP3A4 Inducers (e.g., rifampin, phenytoin) Decreased plasma concentration of Drosdiol's components, risking loss of efficacy.
Metabolic (CYP3A4) Strong CYP3A4 Inhibitors (e.g., ketoconazole) Increased exposure (2- to 3-fold) to drospirenone.
Pharmacodynamic Potassium-Elevating Agents (e.g., ACE Inhibitors, ARBs, Potassium-sparing diuretics) Risk of hyperkalemia due to drospirenone's antimineralocorticoid activity.
Drug-Food Grapefruit Juice Increased drospirenone concentration via inhibition of gut CYP3A4 metabolism.

Patients taking Drosdiol concurrently with any potassium-elevating agent, particularly those with pre-existing renal impairment, require serum potassium monitoring during the first month of treatment. This procedural constraint is due to the heightened, officially documented risk of severe hyperkalemia.

Mechanism of Action

The mechanism of action for Drosdiol involves its two hormonal components acting across three primary mechanistic domains: central suppression, peripheral tissue modification, and receptor antagonism.

Central HPO Axis Suppression

This domain covers the drug's action as an agonist at Estrogen and Progesterone Receptors, which activates a negative feedback loop within the Hypothalamic-Pituitary-Ovarian (HPO) axis. This sustained negative feedback inhibits the release of FSH and LH, leading directly to the physiological consequence of anovulation (preventing the egg release).

Peripheral Tissue Modulation

This mechanism involves the components directly altering peripheral reproductive tissues. The drug causes structural changes in the endometrium (uterine lining), resulting in thinning, and increases the viscosity of the cervical mucus. These actions create physical and chemical barriers that reinforce the central effect through endometrial and cervical modification.

Anti-Mineralocorticoid and Anti-Androgenic Activity

The progestin component, drospirenone, acts as an antagonist at two non-reproductive receptors: the Mineralocorticoid Receptor (MR) and the Androgen Receptor (AR). MR antagonism interferes with the body’s normal regulation of salt and water, which results in a diuretic effect, while AR antagonism reduces the binding of androgens to receptors in peripheral tissues.

Dosage and Administration Information

Administration Guidelines

Drosdiol is a combined hormonal therapy administered exclusively by the oral route in a continuous, cyclic pattern. The standardized regimen requires the consumption of one tablet daily at about the same time each day to maintain a consistent 24-hour interval.


Official Dosing and Cycle Structure

The established daily dose for the active phase is one tablet containing 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol. The medication is supplied in a 28-day regimen package, structured as 24 days of active hormone tablets (typically light pink) followed by four days of inert (placebo) tablets (typically white).

Instruction Detail
Dosing Schedule One tablet taken daily for 28 consecutive days, strictly following the sequential order printed on the blister pack.
Timing with Meals May be taken with or without food, although instructions sometimes suggest taking it after the evening meal or at bedtime.
Cycle Continuation A subsequent 28-day cycle must begin immediately after the last tablet of the previous pack, without any tablet-free delay.

Procedural Conditions

Standard guidelines stipulate clear rules for initiating the first pack, offering both a Day 1 Start and a Sunday Start option. If the first pack is started later than the first day of menses, a non-hormonal back-up contraceptive method must be used for the first seven consecutive days of active tablet taking. Furthermore, product labeling includes detailed, sequential instructions for the management of any missed tablets based on the day of the cycle and whether the tablet was active or inert. The use of the medication is restricted for women with severe renal insufficiency or severe hepatic disease.

Recent Clinical Evidence

Research evidence / Overview of Studies for Drosdiol


Evidence for Use in Pregnancy Prevention (Contraception)

The primary understanding of this medication for preventing pregnancy was evaluated in large-scale clinical trials and long-term research that followed women over extended periods. These research efforts examined how reliably the medicine suppresses the natural process of ovulation, which is a mechanism that studies examined for contraception. The populations was studied for were generally healthy women of reproductive age who were seeking a hormonal method of birth control.

The certainty regarding contraceptive function was evaluated across multiple trials and large observational data sets. However, the data show patterns related to effectiveness being strongly dependent on perfect and consistent use by the individual. Additionally, while the core mechanism is well-documented, continued research examines observational data to monitor the profile of this combination.


Evidence for Management of Moderate Acne Vulgaris

Research exploring the management of moderate acne in women using this combined pill was evaluated in high-standard Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These short-term studies, lasting approximately six months, primarily examined outcomes linked to inflammatory or irritative states, such as the actual count of acne lesions and global ratings of skin appearance. The research was studied for females with moderate facial acne who were also looking for birth control.

Evidence for Symptoms of Premenstrual Dysphoric Disorder (PMDD)

The research into symptoms of PMDD was studied for women seeking contraception who also had prospectively confirmed PMDD. These clinical studies were typically short-term, randomized, and placebo-controlled. The main focus of the research examined outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level.

The trials report how symptoms evolved in the observed populations when comparing the active combination group to the placebo group over the course of the study. The research was observed in some studies to have a notable response in the placebo group. Data are still emerging regarding the full extent of the observed changes, and long-term effects are not fully established regarding the stability of the observed symptom patterns.


What Research Gaps and Uncertainties Remain

The evidence contributes to the broader evidence landscape, but several areas remain uncertain. Limited information for long-term outcomes beyond a few cycles is a consistent limitation for both the acne and PMDD indications. Furthermore, comparative evidence is lacking between this specific drospirenone/ethinyl estradiol combination and all other available contraceptive products regarding certain risks, requiring ongoing surveillance.

Frequently Asked Questions (FAQ)

Common questions about Drosdiol (FAQ)

Q: Is Drosdiol known to cause weight gain, dizziness, fatigue, or affect sleep?

Official reports indicate that commonly observed adverse reactions in individuals using this medicine include weight gain, fatigue (tiredness), and dizziness. Changes in sleep patterns, such as difficulty sleeping, are also noted as a symptom of Premenstrual Dysphoric Disorder (PMDD) that the drug is indicated to manage.


Q: Are there any foods or drinks I need to avoid while using Drosdiol?

Regulatory documents specifically identify an interaction with grapefruit or grapefruit juice. This is because consuming grapefruit can increase the level of the drospirenone component in the body. No other specific food is routinely highlighted in the official warnings.


Q: Does Drosdiol interact with common supplements like multivitamins or herbal teas?

Official guidance warns that certain herbal products, such as St. John's Wort, may reduce the contraceptive effectiveness of the medicine. This happens because these products can affect specific enzymes (like CYP3A4) that process the drug. Official documents advise that patients inform their healthcare provider about all supplements and herbal teas they use.


Q: Are there different strengths of Drosdiol available?

The active ingredients in Drosdiol, drospirenone and ethinyl estradiol, are available in multiple formulations. Regulatory documents describe at least two strengths containing differing amounts of ethinyl estradiol, such as the 3 mg/0.02 mg product and other formulations with 3 mg/0.03 mg.


Q: Does taking Drosdiol affect blood pressure readings?

The medicine is officially contraindicated (should not be used) in women with uncontrolled high blood pressure. Taking it may increase blood pressure in some individuals. Due to this potential risk, regulatory information indicates that patients who use the medication are advised to receive regular blood pressure monitoring.


Q: What is the main difference between Drosdiol and other medicines used for the same purpose? / Why do doctors prescribe Drosdiol over other options?

Pharmacological studies indicate that the progestin component, drospirenone, has unique anti-mineralocorticoid and anti-androgenic activities. This profile indicates that the drug has these specific properties compared to some other combined hormonal contraceptives (CHCs).


Q: Is Drosdiol the same as [Name of common, similar drug]? / Is there a generic version of Drosdiol available?

The specific hormone combination of drospirenone 3 mg and ethinyl estradiol 0.02 mg is available under multiple product brands. Yes, this combination has FDA-approved generic equivalents available, meaning other manufacturers produce the exact same active ingredients at the same strength.


Q: How quickly should I expect to notice anything after starting Drosdiol?

For the primary purpose of preventing pregnancy, the medicine is not considered effective until after the first seven consecutive days of taking the active tablets. It is important that patients follow the specific administration instructions provided by their prescriber and the product labeling.


Q: What happens if I stop taking Drosdiol suddenly?

Regulatory guidance provides specific, detailed instructions for stopping the medication in particular medical scenarios, such as before or after major surgery, or if a serious blood clotting event occurs. These instructions are typically found in the Warnings and Precautions section of the official label.


Q: Can Drosdiol be used by people who are sensitive to certain dyes or fillers? / What are the ingredients in Drosdiol besides the active component?

In addition to the two active hormones, the tablets contain inactive ingredients, such as fillers and coloring agents. The full list of these inactive ingredients, known as excipients, is detailed in the Description section of the official prescribing information.


Q: Can Drosdiol be taken with pain relievers like ibuprofen or acetaminophen?

Official sources note that combined oral contraceptives may affect the way the body processes acetaminophen, a common pain reliever. This change could potentially decrease or delay the effects of the acetaminophen.


Q: Does Drosdiol have any known interactions with alcohol?

The ethinyl estradiol component in the medicine may potentially increase the blood levels and central nervous system effects of alcohol. However, the published data on this specific interaction is sometimes considered contradictory in regulatory documents.


Q: Can Drosdiol be crushed or cut in half if it's hard to swallow?

The official administration instructions require the tablet to be taken whole by mouth at the same time every day. No instructions are provided in the regulatory text to crush, cut, or otherwise modify the tablet.


Q: Has Drosdiol been approved by the FDA or other major regulatory bodies?

Yes, the combination of drospirenone and ethinyl estradiol has been officially approved by the U.S. Food and Drug Administration (FDA) for its labeled indications. This approval is based on the clinical trials and data review required by the agency.


Q: Can Drosdiol affect laboratory test results?

Official labeling indicates that the use of combined oral contraceptives may interfere with the results of certain laboratory tests. These include tests related to hormones, liver function, thyroid function, and specific coagulation (blood clotting) factors.


Q: Is Drosdiol a controlled substance?

No, official drug classification databases confirm that this medication is not classified as a controlled substance in the U.S. It remains a prescription-only medicine.

How should Drosdiol be stored and disposed of?

How to Store and Dispose of Drosdiol

The storage and disposal of drospirenone and ethinyl estradiol tablets are strictly defined by regulatory guidelines to maintain stability and ensure safety.

Storage Requirements

Drospirenone and ethinyl estradiol tablets must be stored at Controlled Room Temperature, which is between 20°C and 25°C (68°F and 77°F). Temperatures are permitted to briefly fluctuate between 15°C and 30°C (59°F and 86°F).

To protect the product from light and moisture, the tablets must remain in the original container or blister packaging as supplied by the manufacturer. The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of primarily through an official drug take-back option or collection program where available. The medication should not be disposed of by flushing down the toilet or pouring into a drain unless specifically instructed by local official disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drosdiol found in:

A-Z Index: